SNYNF: Phase 3 readout — Itepekimab (SAR440340)
Sanofi (SNYNF) has a phase 3 readout expected Q4 2026 in 0 days for Itepekimab (SAR440340) (Chronic Rhinosinusitis With Nasal Polyps).
SNYNF dossier →Biotech Catalyst Calendar — 3880+ catalysts across 163+ companies
Know before the market moves. Every PDUFA date, Phase 2/3 readout, and AdCom — overlaid with institutional positioning so you can see where smart money is already placed.
Data sourced from ClinicalTrials.gov, SEC EDGAR 13F filings, and FDA calendars.
Q4 2026
Q4 2026
Oct 18, 2026
Oct 18, 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
Q4 2026
The nearest catalysts on the calendar, each with the one-line read.
Sanofi (SNYNF) has a phase 3 readout expected Q4 2026 in 0 days for Itepekimab (SAR440340) (Chronic Rhinosinusitis With Nasal Polyps).
SNYNF dossier →Solid Biosciences Inc. (SLDB) has a phase 2 readout expected Q4 2026 in 1 days (Duchenne Muscular Dystrophy).
SLDB dossier →BeOne Medicines Ltd. (BEIGF) has a phase 2 readout expected Oct 18, 2026 in 4 days for BGB-45035 (Rheumatoid Arthritis).
BEIGF dossier →Design Therapeutics, Inc. (DSGN) has a phase 3 readout expected Oct 18, 2026 in 4 days for Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes (Type 2 Diabetes).
DSGN dossier →Incyte Corporation (INCY) has a phase 3 readout expected Q4 2026 in 5 days for Povorcitinib (Prurigo Nodularis).
INCY dossier →PFIZER INC (PFE) has a phase 2 readout expected Q4 2026 in 5 days for PF-07275315 (Atopic Dermatitis).
PFE dossier →Biogen Inc. (BIIB) has a phase 3 readout expected Q4 2026 in 6 days for Litifilimab (Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus).
BIIB dossier →Amgen Inc. (AMGN) has a phase 3 readout expected Q4 2026 in 8 days for Dazodalibep (Sjögren's Syndrome (SS)).
AMGN dossier →ASTRAZENECA PLC (AZN) has a phase 2 readout expected Q4 2026 in 13 days for Volrustomig (Hepatocellular Carcinoma, Biliary Tract Cancer).
AZN dossier →Vertex Pharmaceuticals Inc. (VRTX) has a phase 3 readout expected Q4 2026 in 16 days for VX-121/TEZ/D-IVA (Cystic Fibrosis).
VRTX dossier →ASTRAZENECA PLC (AZN) has a phase 3 readout expected Q4 2026 in 16 days (Asthma).
AZN dossier →Illumina Inc. (ILMN) has a phase 2 readout expected Q4 2026 in 16 days for 18F-MFBG (Parkinson Disease (PD), Lewy Body Dementia (LBD)).
ILMN dossier →Illumina Inc. (ILMN) has a phase 2 readout expected Q4 2026 in 16 days for 18F-metaFluorobenzylguanidine (Heart Failure, Ischemic Cardiomyopathy, ICD Patients).
ILMN dossier →Amgen Inc. (AMGN) has a phase 2 readout expected Q4 2026 in 17 days for anvumetostat (MTAP-deleted NSCLC).
AMGN dossier →Never miss a binary event
Every Monday: the week’s upcoming catalysts, fresh outcomes, and what moved.
A PDUFA (Prescription Drug User Fee Act) date is the FDA's deadline to make a decision on a drug application. The FDA sets this date when it accepts a New Drug Application (NDA) or Biologics License Application (BLA) for review. PDUFA dates are among the most impactful binary events in biotech — stocks can move 50%+ in either direction.
Phase 1 tests safety in a small group. Phase 2 tests efficacy and dosing in a larger group. Phase 3 is a large-scale confirmatory trial that, if successful, supports regulatory filing. Each phase has a data readout that can significantly move a stock's price. We primarily track Phase 2 and Phase 3 readouts as catalysts.
We source catalyst dates from ClinicalTrials.gov trial completion estimates, FDA PDUFA calendars, company press releases, and earnings call guidance. Dates marked as exact have a specific date; others show quarter (Q1, Q2) or half (H1, H2) when precision is limited.
Positive outcomes (trial met endpoints, FDA approval) typically drive sharp price increases, especially in small-cap biotech. Negative outcomes (missed endpoints, complete response letter) can cause 50-80% drops. We track outcomes and label them so you can see which catalysts have already resolved.
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Smart Money Moves
New positions and exits from 20 specialist biotech funds this quarter
Want AI context on every signal? Start free trial →